Steven E. Kahn

Steven E. Kahn

Auto-generated profile, based on publicly available information

Steven E. Kahn

Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington 1 , Seattle, WA

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2006 in Nature
Verified
Journal Article
Open access
PDF file
SKSteven E. Kahn
Steven E. Kahn
RHRebecca L. Hull
Rebecca L. Hull
KUKristina M. Utzschneider
Kristina M. Utzschneider
Obesity is associated with an increased risk of developing insulin resistance and type 2 diabetes. In obese individuals, adipose tissue releases increased amounts of non-esterified fatty acids, glycerol, hormones, pro-inflammatory cytokines and other factors that are involved in the development of insulin resistance. When insulin resistance is accompanied by dysfunction of pancreatic islet β-cells — the cells that release insulin — failure to control blood glucose levels results. Abnormalities in β-cell function are therefore critical in defining the risk and development of type 2 diabetes. This knowledge is fostering exploration of the molecular and genetic basis of the disease and new approaches to its treatment and prevention.

7 December 2006 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
SKSteven E Kahn
Steven E Kahn
SHSteven M Haffner
Steven M Haffner
MHMark A Heise
Mark A Heise
WHWilliam H Herman
William H Herman
RHRury R Holman
Rury R Holman
AGADOPT Study Group
ADOPT Study Group
The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter (10.0 mmol per liter), for rosiglitazone, as compared with metformin or glyburide. Prespecified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, and β-cell function. Kaplan–Meier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with metformin, and 34% with glyburide. This represents a risk reduction of 32% for rosiglitazone, as compared with metformin, and 63%, as compared with glyburide (P<0.001 for both comparisons). The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin. Glyburide was associated with a lower risk of cardiovascular events (including congestive heart failure) than was rosiglitazone (P<0.05), and the risk associated with metformin was similar to that with rosiglitazone. Rosiglitazone was associated with more weight gain and edema than either metformin or glyburide but with fewer gastrointestinal events than metformin and with less hypoglycemia than glyburide (P<0.001 for all comparisons). The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00279045.)


1 March 2014 in The Lancet
Verified
Journal Article
Closed access
SKSteven E Kahn
Steven E Kahn
MCMark E Cooper
Mark E Cooper
SPStefano Del Prato
Stefano Del Prato

10 April 2003 in Diabetologia
Verified
Journal Article
Closed access
PDF file
MCMiriam Cnop
Miriam Cnop
PHPeter Havel
Peter Havel
KUK. M. Utzschneider
K. M. Utzschneider
DCD. B. Carr
D. B. Carr
MSM. K. Sinha
M. K. Sinha
SKS. E. Kahn
S. E. Kahn

12 September 2010 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
SMSeth L Masters
Seth L Masters
ADAisling Dunne
Aisling Dunne
SSShoba L Subramanian
Shoba L Subramanian
RHRebecca L Hull
Rebecca L Hull
GTGillian M Tannahill
Gillian M Tannahill
Luke O'NeillLuke O'Neill
Luke O'Neill